Showing results (261-270 of 294) with videos related to
Sort By:
Pageof 30
Nature Communications|October 14, 2022
Structure of the core human NADPH oxidase NOX2Sigrid Noreng, Naruhisa Ota, Yonglian Sun, et al.Computational and Structural Biotechnology Journal|September 23, 2022
Antibody interfaces revealed through structural miningYizhou Yin, Matthew G Romei, Kannan Sankar, et al.Nature|December 20, 2021
Structural architecture of the human NALCN channelosomeMarc Kschonsak, Han Chow Chua, Claudia Weidling, et al.Plos Genetics|November 3, 2018
Paired Immunoglobulin-like Type 2 Receptor Alpha G78R variant alters ligand binding and confers protection to Alzheimer's diseaseNisha Rathore, Sree Ranjani Ramani, Homer Pantua, et al.Neurosurgical Review|June 9, 2026
Pre-operative MRI-Based Radiomics for Predicting Telomerase Reverse Transcriptase Promoter Mutation Status in Glioma Patients: A Systematic Review and Meta-analysisTina Foodeh, Mohammad Amir Korani, Mohammad Teymourzadeh, et al.Bioorganic Chemistry|September 24, 2021
A novel method to produce synthetic murine CXCL10 for efficient screening of functional variantsJérémie Decalf, Jeffrey Tom, Elaine Mai, et al.Caspian Journal of Internal Medicine|July 25, 2022
COVID-19 and renal involvement in children: a retrospective studyHadi Sorkhi, Mohammadreza Esmaeili Dooki, Maryam Nikpour, et al.Current Therapeutic Research, Clinical and Experimental|January 13, 2022
Post-Marketing Surveillance of a generic Oxaliplatin (AlvoxalⓇ) in Iranian Patients with CancerFarhad Shahi, Mojtaba Gorji, Mehrdad Payandeh, et al.Science Advances|March 11, 2022
Structural basis for HCMV Pentamer receptor recognition and antibody neutralizationMarc Kschonsak, Matthew C Johnson, Rachel Schelling, et al.BMC Pharmacology & Toxicology|July 28, 2022
A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patientsReza Safaei Nodehi, Behjat Kalantari, Jahangir Raafat, et al.Pageof 30